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Abstract
Chronic pain is a global problem affecting up to 20% of the world’s population and has a significant economic, social and
personal cost to society. Sensory neurons of the dorsal root ganglia (DRG) detect noxious stimuli and transmit this sensory
information to regions of the central nervous system (CNS) where activity is perceived as pain. DRG neurons express multiple
voltage-gated sodium channels that underlie their excitability. Research over the last 20 years has provided valuable insights into
the critical roles that two channels, NaV1.7 and NaV1.9, play in pain signalling in man. Gain of function mutations in NaV1.7
cause painful conditions while loss of function mutations cause complete insensitivity to pain. Only gain of function mutations
have been reported for NaV1.9. However, while most NaV1.9 mutations lead to painful conditions, a few are reported to cause
insensitivity to pain. The critical roles these channels play in pain along with their low expression in the CNS and heart muscle
suggest they are valid targets for novel analgesic drugs.
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Introduction
Pain is an important warning system to guard against tissue
damage and disease. Pathological pain, however, has no warn-
ing value and has huge economic, social and personal costs to
society. Chronic pain is a global problem affecting up to 20% of
the world’s population [9, 50]. Sensory neurons of the dorsal
root ganglia (DRG) detect painful stimuli and transmit sensory
information to regions of the central nervous system (CNS) that
perceive pain. DRG neurons are a heterogeneous population of
neurons with distinct functional and histochemical properties
[53, 77]. The DRG contains neurons responding to a variety
of non-noxious stimuli (such as proprioceptors and low-
threshold mechanoreceptors) as well as those responding to
noxious stimuli (nociceptors).
Inflammation and nerve injury sensitise DRG neurons
and result in decreased pain thresholds and/or intense
pain. This can be in part due to increased voltage-gated
sodium channel (VGSC) activity resulting in increased
excitability of DRG neurons [8, 104]. VGSCs consist of
pore-forming α-subunits and auxiliary β-subunits. There
are ten cloned α-subunits and 4 β-subunits. The β-
subunits modulate the localisation, expression and func-
tional properties of α-subunits [12]. Each α-subunit is
composed of four homologous membrane-spanning do-
mains (DI-DIV). Each domain consists of six transmem-
brane segments (S1-S6) [12]. Different α-subunits have
distinct electrophysiological and pharmacological proper-
ties [12, 104], and DRG neurons express multiple α-
subunits that are essential to their ability to fire action
potentials [104].
This review aims to clarify the roles of two VGSC channels
expressed selectively, though not exclusively, in primary sen-
sory neurons in pain pathways, and in the light of evidence
from genetic mouse models and mutations in man.We discuss
the usefulness of these channels as potential drug targets, and
suggest that while our present understanding of function has
grown more complex, targeting these channels either alone or
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in combination may still provide a strategy for analgesic de-
velopment, potentially even for chronic use.
VGSC as targets for analgesic drugs
There are two reasons why VGSCs are attractive targets for
analgesic drugs. Firstly, VGSCs are required for the firing of
action potentials in DRG neurons; therefore, blocking their
activity will reduce pain signalling in painful conditions even
if they were not the primary or only contributor to increased
firing. For example, sensitisation of primary transducing chan-
nels, like the transient receptor potential (TRP) channels, is
often involved in many forms of pathological pain [11, 90,
105]. This sensitisation will lead to greater generator poten-
tials in sensory nerve terminals. However, since VGSCs are
required to initiate an action potential in nerve terminals and to
allow conduction into the CNS, an effective VGSC blocker
can still cancel out the effect of the sensitised TRP channels in
nerve terminals.
Secondly, a few of the VGSC α-subunits expressed in
DRG are either exclusive to or enriched in DRG neurons that
signal pain, with little expression in other DRG neurons, the
CNS, skeletal and heart muscles. Blockers for these subunits
would therefore be expected to produce analgesia without
detrimental side effects. DRG neurons express many of the
cloned α-subunits [104]; however, three subunits (Nav1.7,
Nav1.8 and Nav1.9) meet the above criteria. Not surprisingly,
many pharmaceutical companies are developing and testing
subunit specific Nav1.7, NaV1.8 and NaV1.9 blockers as anal-
gesics [38, 128].
The three α-subunits differ in their biophysical properties
that determine their role in neuronal excitability [104]. The
NaV1.9 channel activates over a negative range of membrane
potentials close to the resting potential and generates a persis-
tent current. Evidence suggests that it is powerfully regulated
by G protein pathways, in a unique way. Therefore, when it is
activated, it contributes to setting the resting membrane poten-
tials of neurons expressing it [23]. Nav1.7 generates a transient
Na+ current, but has a relatively slower rate of inactivation
near the resting potential (slow closed-state inactivation)
allowing the channel to generate persistent currents and mak-
ing it a so-called threshold channel [22, 25]. Nav1.8 has a
relatively depolarised activation voltage (~ − 20 mV) com-
pared with Nav1.7 and Nav1.9 [2, 104]; thus, Nav1.8 activa-
tion comes after and perhaps subsequent to the activation of
Nav1.9 and Nav1.7 channels. Nonetheless, Nav1.8’s
depolarised inactivation and more rapid recovery from inacti-
vation allow it to contribute to repetitive firing, for example
[104]. This review will focus on NaV1.9 and Nav1.7 subunits
since their biophysical properties allow them both to influence
pain thresholds through setting the membrane potential and
action potential threshold in DRG neurons.
Role of Nav1.7 in pain
Nav1.7 was cloned from PC12 cells in 1997 [118]. At that
time, NaV1.8 and NaV1.3 channels were already under the
spotlight and their role in pain was actively being investigated.
NaV1.8 was cloned in 1996 and its strong expression in me-
dium and small sensory neurons (the sizes of most
nociceptors) made it the best and most obvious target for an-
algesic drug development [2]. The NaV1.8 knockout mouse
was reported 3 years later and although it showed a pain def-
icit, its phenotype was compromised by a compensatory up-
regulation of Nav1.7 [3] with clear functional consequences
[3, 89]. However, knockdown of NaV1.8 by antisense oligo-
nucleotides in adult rats inhibited neuropathic pain [75, 129].
The difference could be due to the timing of the deletion
(embryonic versus adult) or the animal model used (mouse
versus rat). In contrast to Nav1.8, the expression pattern of
Nav1.3 does not suggest it would be a useful drug target.
Nav1.3 is expressed throughout the nervous system and its
expression is highest during embryonic development and de-
creases postnatally [121]. However, Nav1.3 is the only chan-
nel that is re-expressed in DRG following nerve injury and
diabetes [122]. This made it a potentially viable target for
analgesics. However, mice lacking Nav1.3 do not show any
deficits in pain phenotype [92].
Nav1.7 became the focus of the pain field in 2004 with the
publication of two papers [91, 125]. The first paper identified
a mutation in SCN9A (the gene coding for Nav1.7) as the cause
for a rare inherited pain condition known as primary
erythromelalgia (PEM). PEM symptoms start at early age with
episodes of pain in the extremities (usually in the feet) that are
triggered by exposure to heat or walking [125]. The second
paper reported the complete absence of inflammatory pain in a
conditional mouse lacking Nav1.7 in most nociceptors [91].
The conditional ablation in nociceptors was achieved using a
Cre driver mouse line where Cre is expressed by the Nav1.8
promotor [113]. The complete loss of all inflammatory pain
and mechanical pressure after ablation of Nav1.7 in
nociceptors [91] excited the pain field and stimulated drug
discovery programmes at several pharmaceutical companies
[38, 128]. A conditional mouse was generated because global
deletion of Nav1.7 in mouse proved to be lethal [91]. Global
knockout pups were born alive but failed to feed and died
within 24 h. Hand feeding and special husbandry arrange-
ments allow Nav1.7 global KOs to survive to adulthood
[49]. Inducing Nav1.7 ablation in adult mice causes pain def-
icits without detrimental effects [107].
Remarkab ly , the symptoms of PEM pat i en t s
complemented the phenotype of the conditional Nav1.7 null
mice. While pain can be triggered by mechanical pressure on
the feet (walking and exercise), conditional null mutants
showed a complete loss of pain to mechanical pressure.
While PEM patients showed signs of inflammatory pain (heat,
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redness and occasionally swelling of the feet), conditional null
showed a complete loss of inflammatory pain. This helped
support the hypothesis that blocking Nav1.7 in humans would
significantly reduce pain signalling. However, the mouse
study raised significant questions. Firstly, is the role of
Nav1.7 in pain signalling in humans as critical as it is in mice,
or in other words, would the loss or block of Nav1.7 in humans
lead to the all or none loss of pain seen in mice? Furthermore,
if this is the case, then would the loss or block of Nav1.7 in
humans result in lethality (as it did in mice)? These questions
were critical for the validity of Nav1.7 as a drug target. These
questions were answered in 2006 when it was reported that a
loss of function mutation in SCN9A causes complete insensi-
tivity to pain (CIP) [19]. In CIP patients, perception of non-
noxious touch and warmth is not affected, whereas perception
of noxious heat, pressure and injury pain is completely lost.
CIP patients confirmed that Nav1.7 plays as a critical role in
pain signalling in humans as it does in mice. Importantly, loss
of Nav1.7 did not lead to lethality nor any significant disability
(CIP patients are anosmic due to the expression of Nav1.7 in
the olfactory epithelia [135]). A second heritable painful con-
dition was mapped to a gain of function mutation in SCN9A in
the same year (2006). Paroxysmal extreme pain disorder
(PEPD, initially known as familial rectal pain), was found to
be caused by a gain of functionmutation in the Nav1.7 channel
[45]. The four papers between 2004 and 2006 provided very
strong evidence that Nav1.7 is a critical player in pain signal-
ling, catapulting it to the top of the list of analgesic drug
targets. Since then, human geneticists have identified scores
of mutations causing PEM, PEPD, CIP and small fibre neu-
ropathy (SFN).
Primary Erythromelalgia
Primary erythromelalgia is an autosomal dominant condition
caused by a mutation in the SCN9A gene. The condition was
first mapped to SCN9A in 2004 by Yang et al. [125]. The
proband suffered from bilateral episodes of burning pain in
their hands and feet that started during their childhood and
continued throughout their life. During the attacks, the feet
and hands became warm and red. The pain episodes were
triggered by exercise or exposure to heat. The proband had
the nonsense mutation L858H which is located in the second
domain, Fig. 1. Characterisation of the channel’s biophysical
properties showed that the mutation shifted the activation volt-
age about 12mV in the hyperpolarising direction resulting in a
reduced threshold for channel opening and thus increased ex-
citability [24]. Since the first report, several mutations have
been reported that cause PEM, listed in Table 1 in chronolog-
ical order. Symptoms appear early in life although late onset
cases have been reported [16, 21]. All PEM mutations cause
similar changes to the biophysical properties of Nav1.7,
involving a shift of the activation voltage to hyperpolarised
potentials [30], and where the magnitude of the shift seems to
affect the severity of the symptoms [55]. Furthermore, PEM
mutations tend to cluster in domains I and II of the channel
protein, Fig. 1.
Treatment for PEM patients includes avoidance of the con-
ditions that trigger pain (i.e. heat and physical pressure on the
feet). Patients typically resort to foot lifting, cooling feet by
fans or immersing them in water or iced water to reduce or
relief pain. Although immersion in cold water is effective for
mild cases, it can result in ulceration and maceration of foot
skin leading to infection [19, 116]. Recently, it has been re-
ported that behavioural therapy reduced dependence on water
immersion in PEM patients [67]. There is no consensus on
pharmacotherapy. Among effective drugs are non-selective
sodium blockers (lignocaine, mexiletine and carbamazepine)
[82, 116] which have been shown to inhibit NaV1.7 [120,
133].
Paroxysmal extreme pain disorder
Paroxysmal extreme pain disorder (PEPD, formerly known as
familial rectal pain syndrome), is caused by gain of function
mutations in SCN9A that alter the biophysical properties of the
Nav1.7 channel [45]. There are several similarities between
PEPD and PEM. Both are autosomal dominant conditions
with symptoms starting early in childhood (PEPD is observed
in infants [17]). PEPD is characterised by episodes of severe
burning pain in the rectal, ocular and mandibular areas accom-
panied by flushing of the skin. Pain in PEPD patients is trig-
gered by otherwise innocuous mechanical stimulation (defe-
cating, chewing and yawning) and warmth of the affected
areas. However, functional characterisation of mutant Nav1.7
channels showed that they have normal activation voltages
(unlike PEM mutations). In contrast, PEPD mutations cause
a depolarising shift in inactivation voltages with incomplete
channel inactivation, leading to a persistent current and in-
creased excitability [7, 45, 119]. Table 2 lists reported
SCN9A mutations that are found in PEPD patients. PEPD
mutations tend to cluster in domains III and IV of the channel
protein, Fig. 2. Despite the severity of the pain, PEPD patients
responded well to the anti-epileptic drug carbamazepine
[117].
Heritable small fibre neuropathy
Small fibre neuropathy (SFN) is caused by damage to thinly
myelinated and unmyelinated nerve fibres. SFN is often
characterised by late onset, bilateral burning pain to the hands
and feet. SFN is also associated with disturbances to autonom-
ic functions like sweating, dryness in the eyes or mouth and
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disturbance to bowel and bladder functions [117]. Autonomic
symptoms are not reported in both PEM and PEPD. Diagnosis
is usually confirmed by a decrease in intra-epidermal fibre
density (IDFD) in skin biopsies. Several conditions can cause
SFN, and these include diabetes and autoimmune disease [52,
112]. About 50% of SFN cases are idiopathic, with no obvious
aetiology [112]. The dominant pattern of inheritance of SFN
in some cases of idiopathic SFN suggested mutations in a
single gene [52, 112]. Mutations in the three peripheral
VGSCs, Nav1.7 [10], Nav1.8 [44] and Nav1.9 [63] channels,
have been found in heritable SFN cases.
Characterisation of Nav1.7 channels in SFN patients, listed
in Table 3, showed that they would cause hyperexcitability
[43, 62]; however, it is not clear how this leads to a small fibre
neuropathy and why it is of late onset. Nav1.7 channel muta-
tions linked to SFN are not localised to a particular region
within the channel but many are clustered in the first intracel-
lular loop between domains I and II, Fig. 3. Recently a clinical
trial has found lacosamide to be efficacious in reducing pain
and well-being of SFN patients with SCN9A mutations [27];
however, the effect was linked to subset of SCN9A mutations
[74].
Role of Nav1.7 in epilepsies
Although the expression of Nav1.7 in the human brain is
poorly characterised, there is emerging evidence that Nav1.7
plays some role in modulating excitability in the brain. It is
known that CIP patients suffer from the loss of the sense of
smell due to expression of Nav1.7 in the olfactory epithelia
[135] and a patient with the PEMmutation N1245S displayed
high olfactory sensitivity [54]. However, CIP patients are not
reported to suffer from brain-related symptoms. Nonetheless,
several papers have recently reported mutations in SCN9A in
patients with various types of epilepsies, Table 4. These mu-
tations are mostly localised to the DI-DII part of the channel,
Fig. 4. The above suggests that while a loss of Nav1.7 function
has no detrimental effect on the brain, altered or increased
Nav1.7 function does. Therefore, further research is needed
to provide insights onto the type of cells that express Nav1.7
(types of neurons? any in glia?) in the brain. Furthermore,
knock-in models will help to explore how the mutations cause
epilepsy rather than act as modifiers to changes in other genes
(e.g. SCN1A, SCN2A and SCN3A). Finally, it is intriguing that
a few mutations (e.g. Q10R) cause PEM in some patients, and
epilepsy in others. This may suggest that variations in the
functional expression of other genes or epigenetic changes
influence the biological consequences of mutations in Nav1.7.
Complete insensitivity to pain
Complete insensitivity to pain is characterised by loss of all
pain sensations throughout patient’s life. SCN9A loss of func-
tion mutations cause an autosomal recessive CIP [19, 34].
Several mutations have been identified, and most are non-
sense mutations causing truncated proteins, Table 5. Most of
the mutations are located within domains I and II, Fig. 5.
There is recent evidence that the CIP phenotype involves
changes to endogenous opioids [87, 97]; however, this was
not observed in a rat null model [14].
Role of Nav1.9 in pain
Nav1.9 (gene name SCN11A) is a tetrodotoxin-resistant (TTX-
r), so-called persistent Na+ current, with clear evidence for
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Fig. 1 Topological representation
of SCN9A mutations that cause
PEM. A VGSC α-subunit con-
sists of four homologous domains
(DI-DIV). Each domain consists
of six transmembrane segments.
Three intracellular loops (L1-L2)
connect the four domains. Note
that most mutations are localised
to domains I and II. Structures are
not drawn to scale
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functional expression in nociceptive primary sensory neurons
in the dorsal root ganglia (DRG) and trigeminal (e.g. [6, 23]),
and the AH cells of the myenteric plexus in the gut [18, 102].
The human clone (first named as SCN12A, 73% identical with
rat SCN11A) [68] had initial reported expression in the pla-
centa, spleen, small intestine, spinal cord and brain (potential-
ly neurons and glia). In primary sensory neurons, it has been
associated with nerve endings in the tooth pulp and cornea
using immunohistochemical methods, and evidence suggests
it is found distributed along IB4+ axons in the sciatic nerve
(e.g. [28, 47, 95]); furthermore, the channel have been located
to gut afferents [60, 61] and also to the bladder [101] using
electrophysiological methods in gene knockout mice.
The functional properties of the channel currents were first
identified in Nav1.8 knockout mouse sensory neurons,
because under these circumstances, the channel generates
the only tetrodotoxin-resistant (TTX-r) Na+ current [23, 84].
The channel produces a Na+ current in sensory neuron cell
bodies that has ultra-slow activation and inactivation kinetics.
It gives rise to a persistent, non-inactivating current operating
over the negative portion of its activation membrane potential
range, allowing it to act as a ‘threshold channel’, and to con-
tribute to setting the membrane potential. Its unusual kinetic
properties and negative activation range produce ‘plateau po-
tentials’ that amplify applied or transduced sub-threshold
depolarisations and massively prolong them in duration
(Fig. 6). It is worth noting that Nav1.9 has activation kinetics
that are too slow to directly contribute to impulse firing.
Intracellular dialysis of the non-hydrolysable GTP ana-
logue, GTP-γ-S, upregulated the Nav1.9 current with no
Table 1 SCN9A mutations that
cause PEM in order of their
publication
Mutation Notes on effect Ref
L858H [125]
I848T [33, 125]
L858F [33]
N395K [33]
F216S [33]
P610T [33]
R1150W [33]
F1449V [29]
S241T [86]
A863P [59]
I136V Late onset + reduced intradermal fibre density [78]
A1632E Causes PEM and PEPD-like symptoms [39]
Q10R Late onset [55]
V400M Carbamazepine responsive [46]
L823R Shifts fast inactivation to more negative potentials, unusual in PEM [76]
S211P [40]
I234T Sitting and heat trigger pain, one of the largest shift in activation voltage. [1]
G616R [16]
Del-L955 Large hyperpolarised shift in activation voltage with a large shift in
inactivation voltage in the same direction leading to mild
symptoms
[15]
I228M [41]
Q875E Severe pain [110]
Q10K [72]
V1316A [42, 123]
A1746G [21]
W1538R Described as W1550R in [26] [21]
A1632T [35]
L245 V Incomplete fast inactivation but no shift in activation voltage [37]
A1632G [126]
G856R PEM with impaired limb development [115]
F826Y [124]
P187L [131]
N1245S [54]
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changes in current kinetics, recorded in voltage-clamp. It was
also found that at a membrane potential of near − 60 mV,
functional upregulation of the current can cause sensory neu-
rons to fire rhythmically and spontaneously, at low frequency
(Fig. 6) [6]. The current could be upregulated following the
activation of ATP receptors, deduced to be P2Y, operating
through a probable Gq/11 pathway and PKC [5, 6], and such
a pathway has later been confirmed to be a contributor to
modifying the firing properties of gut afferents.
There are several mouse knockouts of SCN11A reported in
the literature and these have been associated with an elimina-
tion of the GTP-γ-S-upregulated current in primary sensory
neurons [94] and a complementary reduction in forms of in-
flammatory pain following exposure to PGE2 [4] and including
the formalin and CFA tests [99]—consistent with a role of
Nav1.9 in inflammatory pain in both the skin and gut. A likely
role for Nav1.9 in the control of normal gut motility, attributable
to altered plexus function, seems consistent with the effects of
mutation in human carriers and gain of function is associated
with constipation (e.g. [69]).With these facts in mind, it may be
possible to understand the defects in pain signalling found in
humans with rare, heritable mutations in SCN11A.
Painful and painless Nav1.9 channelopathies
About 20 mutations have been reported for SCN11A, Table 6.
All follow a dominant inheritance pattern. Most mutations
have been confirmed to lead to a gain of function. No loss
of function mutations have been reported to date which could
be because such mutations cause mild or no effect on pain
signalling in humans (given the phenotype of knockout mice,
it is very unlikely that human loss of function mutation causes
lethality). It is also possible that the loss or reduction of in-
flammatory pain may mean such individuals are unlikely to
have a reason to visit the doctor!
The persistent nature of Nav1.9 currents and the negative
activation voltage dependence make the channel functionally
unique. It is proposed to act as a threshold channel in periph-
eral nociceptors, so gain of function mutations associated with
facilitated activation would be expected to give rise to painful
neuropathy, because the threshold for action potential gener-
ation is reduced. Indeed, SCN11A mutations result in two
painful conditions, familial episodic pain [65, 80, 93, 130]
and painful small fibre neuropathy [48, 57, 63]. In familial
episodic pain, painful episodes centre on regions on the arms
and legs; in addition, there are age-related decreases of pain,
suggesting real age-related changes in gene expression.
Painful episodes (lasting 10 s of minutes) are associated with
rainy days, cold temperature and commonly also fatigue;
some are associated with gut motility symptoms. Further,
drugs acting as NSAIDs or anti-pyretics, such as ibuprofen,
appear to be able to ameliorate these symptoms. Patients with
SCN11A-related small fibre neuropathy experience pain, tin-
gling and numbness in their arms and legs. Patients may
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Fig. 2 Topological representation
of mutations that cause PEPD in
the α-subunit of NaV1.7. Note
that most mutations are localised
in L3 and domains III and IV.
Structures are not drawn to scale
Table 2 SCN9Amutations that cause PEPD in order of their publication
Mutation Notes on effect Ref
R996C [45]
V1298D [45]
V1298F [45]
V1299F [45]
I1461T [45]
F1462V [45]
T1464I [45]
M1627K [45]
A1632E Channel displays properties of PEM and PEPD [39]
G1607R [17]
I228M Produces PEM-like symptoms as well [41]
R185H [85]
L1612P [114]
V1740L Patients suffer from headache [66]
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experience diarrhoea which is consistent with expression of
Nav1.9 in the gut [130].
Surprisingly, a few SCN11A gain of function mutations
cause a complete insensitivity to pain [70, 79, 98]. Several
Table 3 Mutations that cause
SCN9A-linked SFN in order of
their publication
Mutation Notes on effect Ref
I720K
D623N
M932L
V991L
R185H
I228M
M1532I
I739V
Mutations have various impacts on channel properties
but all lead to hyperexcitability.
[43]
G856D Shifts activation voltage to more negative potentials.
Shifts fast inactivation to more positive potentials.
Causes hyperexcitability.
[62]
K40E
N336T
V518F
E519K
T531N
A678E
F710V
W719C
I720K
P756T
M757W
Y990C
M1230T
R1279Q
R1620L
Y1657S
V1754F
D1971V
Functional properties uncharacterised [36]
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are not drawn to scale
871Pflugers Arch - Eur J Physiol (2020) 472:865–880
possible explanations for how enhanced channel function
leads to reduced neuronal excitability have been suggested
[31], although arguments concerning modifications of
channel-gating kinetics as the primary cause seem incomplete
and are based on voltage-clamp recordings whose interpreta-
tion may not be straightforward. It is thought that increased
activation/inactivation-gating overlap (or window current)
depolarise the Nav1.9 expressing neurons. This prolonged
depolarisation causes rapidly gating Na+ channels (e.g.
Nav1.7 and Nav1.8) to enter the inactivated state [64]. Since
these channels underpin action potential generation and prop-
agation, the depolarizing block of Nav1.7 and Nav1.8 in nerve
endings leads to an overall decrease in excitability. It was
noted that the mutations that lead to CIP are those that pro-
duced the largest shift in the activation threshold of the chan-
nel, whereas those that lead to familial episodic pain and pain-
ful small fibre neuropathy cause smaller shifts, Table 6 [31].
Also of note, SCN11A CIP mutations are all localised to trans-
membrane segment 6, Fig. 7. However, several issues are
difficult to reconcile with the above explanation for the pain-
less phenotype. Firstly, Nav1.9 is expressed in the IB4
+ subset
of neurons and not in all DRG neurons (at least in rodents).
Therefore, a depolarising block in this subset of neurons alone
is not expected to cause a complete loss of pain. Second,
NaV1.8 which is expressed in most nociceptors (i.e. in same
neurons as Nav1.9) is a channel known to operate at more
depolarised membrane potentials and can maintain
excitability, even in the face of a depolarised membrane po-
tential [56, 103, 111, 134].
Concluding remarks
In the past 20 years, mouse models and human genetics have
confirmed that Nav1.7 and Nav1.9 play critical roles in pain
signalling. The link between genotype and phenotype for mu-
tations in both channels is poorly understood. Symptomsman-
ifest in the extremities (mainly in the feet/legs) in most human
conditions. In Nav1.7 channel mutations, there is a link be-
tween mutations that cause enhancement of activation to PEM
and mutations that cause incomplete inactivation to PEPD.
The physiological or microanatomical basis for these associ-
ations in terms of nerve ending function is only partly under-
stood. In NaV1.9 channel mutations, a clear understanding of
why most gain of function mutations cause painful conditions
while those affecting segment 6 cause insensitivity to pain is
also lacking, although insensitivity to pain is hypothesised to
be caused by reduced excitability due to a depolarising block
[121, 122].
Nonetheless, available evidence confirms a critical role for
both channels in pain earning them a position in the list of
potential drug targets. Ablation of Nav1.8 and Nav1.9 in mice
does not lead to lethality or any observable detrimental effects.
Ablation of Nav1.7 in human [19] and in adult mice [107]
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1 Q10R
2 G327E
1
2
3
5
6
7
L1
3 R429C
4 A442T
5 N641Y
4
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6 I775M
DIV
7 Y1958C
Fig. 4 Topological representation
of SCN9A mutations that are
linked to epilepsies
Table 4 Mutations that cause
epilepsies in order of their
publication
Mutation Notes on effect Ref
N641Y Knock-in mice exhibit significantly reduced thresholds to electrically induced seizures. [109]
Q10R From patient with febrile seizures plus [13]
G327E [127]
G327E From twin patients with idiopathic focal epilepsy with Rolandic spikes [81]
I775M From patient with febrile seizures [32]
R429C From patient with febrile seizures plus [32]
A442T From patient with genetic epilepsy with febrile seizures plus [32]
Y1958C From patient with genetic epilepsy with febrile seizures plus [132]
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does not lead to lethality. Reassuringly, there are no reported
respiratory or behavioural abnormalities as a result of the ab-
sence of any one of these three channels in mouse and human.
Yet important challenges for VGSC blockers in chronic pain
remain, developing subunit-specific blockers being the first.
This is important considering that VGSC blockers would need
to be administered regularly to treat chronic pain and perhaps
at higher doses for breakthrough pain, when pain is severe.
Therefore, VGSC blockers would need to be safe for long-
term administration. The development of specific and effec-
tive small molecule inhibitors of Nav1.7 is still elusive, despite
efforts by several pharmaceutical companies [38, 71, 128].
The second challenge is the extent of Nav1.7 inhibition re-
quired for analgesia in vivo. Given that CIP carriers have
normal pain phenotype, an Nav1.7 blocker may need to reduce
channel activity to a level well below 50% to produce
analgesia.
The contribution of the endogenous opioid system to the
phenotype of the SCN9A CIP raises the question of whether
the CIP phenotype is a direct consequence of the loss of
Nav1.7 [87, 97]. Several papers have provided complementary
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Fig. 5 Topological representation
of SCN9A mutations that cause
CIP. Mutations associated with
CIP are widely distributed
throughout the α-subunit
Table 5 SCN9A mutations that cause complete insensitivity to pain
(CIP) in order of their publication
Mutation Ref
S459X [19]
I767X [19]
W897X [19]
R277X [51]
Y328X [51]
E693X
Splice junction mutation intron 23-24
[51]
R830X [51]
F1200L fs [51]
R1488X [51]
K1659X
I1235L fs
[51]
W1689X [51]
R523X [73]
R896Q [20]
K370Q
G375A fs
[108]
E919X [96]
M1190X [106]
G1822 fs [100]
R896G
Q369X
[83]
Fig. 6 a Upregulation of Nav1.9 in an Nav1.8 knockout neuron,
following the introduction of 500 μM GTP-γ-S into the cell interior for
12 min. b Upregulation of Nav1.9 using intracellular GTP-γ-S gives rise
to changes in the firing properties of Nav1.8 knockout neuron, with re-
ductions in current and voltage threshold, recorded from a holding poten-
tial of − 90 mV. The upregulated current gives rise to plateau potentials
(arrow). Reproduced from [6], with permission
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evidence that the loss of Nav1.7 reduces the excitability of
DRG neurons per se. Deletion of Nav1.7 causes an increase
in action potential threshold in small-diameter DRG neurons
[107]. Deletion of Nav1.7 causes a major decrease in DRG
neuron responsiveness to the VGSC opener veratridine [89].
Mechanically evoked spiking of C-fibres in the skin-nerve
preparation was reduced in Nav1.7 KOmice [49]. No changes
in the expression of other VGSC channels were reported in the
Nav1.7 KO mouse to contribute to the observed reduced ex-
citability of DRG [107]. Furthermore, pain deficits in a rat
model of NaV1.7 deletion were not reversed by the opioid
receptor antagonist naloxone [14]. Therefore, although an
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16 V1184A
17 I1293V
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12
Fig. 7 Topological representation
of SCN11Amutations. Notice that
all CIP causing mutations (red)
are located in the transmembrane
segment 6
Table 6 SCN11A mutations that
cause painful and painless human
conditions. Mutations causing
painless condition are associated
with big shifts in either their
activation or inactivation voltages
Mutation Notes on effect Ref
L811P CIP
Activation voltage shifted by − 26 mV
[79]
R225C
A808G
Episodic pain
Increase current density
No effect on activation and inactivation voltages
[130]
I381T
K419N
A582T
A681D
A842P
L1158P
F1689L
Painful neuropathy
I381T: activation voltage shifted by − 6.7 mV
L1158P: activation voltage shifted by − 6.9 mV
[63]
G699R Painful neuropathy
Activation voltage shifted by − 10.1 mV
[57]
V1184A Episodic pain
Activation voltage shifted by − 17 mV
[80]
R222S
R222H
Episodic pain [93]
R222H Episodic pain
Activation voltage shifted by − 6.4 mV
[58]
L1302F CIP [98]
N1169S
I1293V
PEM-like pain [131]
L396P CIP
Deactivation voltage shifted by − 22.8 mV
[70]
L1302F CIP [64]
N820Y Painful neuropathy [48]
N816K Episodic pain [65]
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increase in spinal cord opioid synthesis would reduce signal
transmission at the first synapse in CIP patients, the loss of
NaV1.7 has a profound effect on the excitability of DRG neu-
rons (i.e. expected to affect the initiation of the pain signal in
the periphery).
The lack of reported Nav1.9 loss of function mutations may
indicate that its loss does not lead to a major phenotype in
humans, or at least does not make people go to the doctor,
raising doubts as to whether a blocker would lead to a major
analgesic effect. Finally, considering that nociceptors express
at least two of the peripheral VGSC subunits (Nav1.7, Nav1.8
and Nav1.9), an effective analgesic strategy may ultimately
result from a combination of blockers against these subunits
to have additive and synergistic effects on nociceptors. The
effectiveness of various drug combinations to reduce neuronal
excitability can only be measured in DRG neurons because
they express the target VGSCs at biologically relevant levels.
Equally important, for the evaluation of any drug combina-
tion, is the potential effects on non-nociceptors as well as
nociceptors. We recently described a relevant assay [88] and
provided proof-of-concept data that showed a combination of
Nav1.7 and Nav1.8 blockers produced a reduction in the ex-
citability of DRG neurons close to that measured in Nav1.7
KO [89]. Changing the constituents and doses in VGSC
blocker combinations may enable clinicians to manage chron-
ic pain safely over the long term.
Acknowledgements MAN is grateful to Yusef Nassar for the proof read-
ing and suggestions on the manuscript.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Ahn HS, Dib-Hajj SD, Cox JJ, Tyrrell L, Elmslie FV, Clarke AA,
Drenth JP, Woods CG, Waxman SG (2010) A new Nav1.7 sodi-
um channel mutation I234T in a child with severe pain. Eur J Pain
14:944–950. https://doi.org/10.1016/j.ejpain.2010.03.007
2. Akopian AN, Sivilotti L, Wood JN (1996) A tetrodotoxin-
resistant voltage-gated sodium channel expressed by sensory neu-
rons. Nature 379:257–262. https://doi.org/10.1038/379257a0
3. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J,
Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC,
Dickenson AH, Wood JN (1999) The tetrodotoxin-resistant
sodium channel SNS has a specialized function in pain pathways.
Nat Neurosci 2:541–548. https://doi.org/10.1038/9195
4. Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP,
Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ,
Chessell IP, Tate S, Green PJ, Woolf CJ (2006) The voltage-
gated sodium channel Na(v)1.9 is an effector of peripheral inflam-
matory pain hypersensitivity. J Neurosci 26:12852–12860. https://
doi.org/10.1523/JNEUROSCI.4015-06.2006
5. Baker MD (2005) Protein kinase C mediates up-regulation of
tetrodotoxin-resistant, persistent Na+ current in rat and mouse
sensory neurones. J Physiol 567:851–867. https://doi.org/10.
1113/jphysiol.2005.089771
6. Baker MD, Chandra SY, Ding Y, Waxman SG, Wood JN (2003)
GTP-induced tetrodotoxin-resistant Na+ current regulates excit-
ability in mouse and rat small diameter sensory neurones. J
Physiol 548:373–382. https://doi.org/10.1113/jphysiol.2003.
039131
7. Bennett DL, Woods CG (2014) Painful and painless channelopa-
thies. Lancet Neurol 13:587–599. https://doi.org/10.1016/S1474-
4422(14)70024-9
8. Beyak MJ, Vanner S (2005) Inflammation-induced hyperexcit-
ability of nociceptive gastrointestinal DRG neurones: the role of
voltage-gated ion channels. Neurogastroenterol Motil 17:175–
186. https://doi.org/10.1111/j.1365-2982.2004.00596.x
9. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006)
Survey of chronic pain in Europe: prevalence, impact on daily life,
and treatment. Eur J Pain 10:287–333. https://doi.org/10.1016/j.
ejpain.2005.06.009
10. Brouwer BA,Merkies IS, GerritsMM,Waxman SG, Hoeijmakers
JG, Faber CG (2014) Painful neuropathies: the emerging role of
sodium channelopathies. J Peripher Nerv Syst 19:53–65. https://
doi.org/10.1111/jns5.12071
11. Caterina MJ, Pang Z (2016) TRP channels in skin biology and
pathophysiology. Pharmaceuticals (Basel) 9. https://doi.org/10.
3390/ph9040077
12. Catterall WA (2017) Forty years of sodium channels: structure,
function, pharmacology, and epilepsy. Neurochem Res 42:2495–
2504. https://doi.org/10.1007/s11064-017-2314-9
13. Cen Z, Lou Y, Guo Y, Wang J, Feng J (2017) Q10R mutation in
SCN9A gene is associated with generalized epilepsy with febrile
seizures plus. Seizure 50:186–188. https://doi.org/10.1016/j.
seizure.2017.06.023
14. Chen L, Effraim P, Carrara J, Zhao P, Dib-Hajj FB, Dib-Hajj SD,
Waxman SG (2020) Pharmacological characterization of a rat
Nav1.7 loss-of-function model with insensitivity to pain. Pain.
https://doi.org/10.1097/j.pain.0000000000001807
15. Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JP,
Waxman SG (2011) Deletion mutation of sodium channel
Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation
modulates dorsal root ganglion neuron hyperexcitability. Brain
134:1972–1986. https://doi.org/10.1093/brain/awr143
16. Choi JS, Cheng X, Foster E, Leffler A, Tyrrell L, TeMorsche RH,
Eastman EM, Jansen HJ, Huehne K, Nau C, Dib-Hajj SD, Drenth
JP, Waxman SG (2010) Alternative splicing may contribute to
time-dependent manifestation of inherited erythromelalgia. Brain
133:1823–1835. https://doi.org/10.1093/brain/awq114
17. Choi JS, Boralevi F, Brissaud O, Sanchez-Martin J, Te Morsche
RH, Dib-Hajj SD, Drenth JP, Waxman SG (2011) Paroxysmal
extreme pain disorder: a molecular lesion of peripheral neurons.
Nat Rev Neurol 7:51–55. https://doi.org/10.1038/nrneurol.2010.
162
18. Coste B, Osorio N, Padilla F, Crest M, Delmas P (2004) Gating
and modulation of presumptive NaV1.9 channels in enteric and
spinal sensory neurons. Mol Cell Neurosci 26:123–134. https://
doi.org/10.1016/j.mcn.2004.01.015
875Pflugers Arch - Eur J Physiol (2020) 472:865–880
19. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E,
Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-
Gazali L, Hamamy H, Valente EM, Gorman S, Williams R,
McHale DP, Wood JN, Gribble FM, Woods CG (2006) An
SCN9A channelopathy causes congenital inability to experience
pain. Nature 444:894–898. https://doi.org/10.1038/nature05413
20. Cox JJ, Sheynin J, Shorer Z, Reimann F, Nicholas AK, Zubovic L,
Baralle M, Wraige E, Manor E, Levy J, Woods CG, Parvari R
(2010) Congenital insensitivity to pain: novel SCN9A missense
and in-frame deletion mutations. Hum Mutat 31:E1670–E1686.
https://doi.org/10.1002/humu.21325
21. Cregg R, Laguda B, Werdehausen R, Cox JJ, Linley JE, Ramirez
JD, Bodi I, Markiewicz M, Howell KJ, Chen YC, Agnew K,
Houlden H, Lunn MP, Bennett DL, Wood JN, Kinali M (2013)
Novel mutations mapping to the fourth sodium channel domain of
Nav1.7 result in variable clinical manifestations of primary
erythromelalgia. NeuroMolecular Med 15:265–278. https://doi.
org/10.1007/s12017-012-8216-8
22. Cummins TR, Howe JR, Waxman SG (1998) Slow closed-state
inactivation: a novel mechanism underlying ramp currents in cells
expressing the hNE/PN1 sodium channel. J Neurosci 18:9607–
9619
23. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN,
Waxman SG (1999) A novel persistent tetrodotoxin-resistant so-
dium current in SNS-null and wild-type small primary sensory
neurons. J Neurosci 19:RC43
24 . Cummins TR, Dib -Ha j j SD, Waxman SG (2004)
Electrophysiological properties of mutant Nav1.7 sodium chan-
nels in a painful inherited neuropathy. J Neurosci 24:8232–8236.
https://doi.org/10.1523/JNEUROSCI.2695-04.2004
25. Cummins TR, Sheets PL, Waxman SG (2007) The roles of sodi-
um channels in nociception: implications for mechanisms of pain.
Pain 131:243–257. https://doi.org/10.1016/j.pain.2007.07.026
26. Dabby R, Sadeh M, Gilad R, Lampl Y, Cohen S, Inbar S,
Leshinsky-Silver E (2011) Chronic non-paroxysmal neuropathic
pain-novel phenotype of mutation in the sodium channel SCN9A
gene. J Neurol Sci 301:90–92. https://doi.org/10.1016/j.jns.2010.
10.006
27. de Greef BTA, Hoeijmakers JGJ, Geerts M, Oakes M, Church
TJE, Waxman SG, Dib-Hajj SD, Faber CG, Merkies ISJ (2019)
Lacosamide in patients with Nav1.7 mutations-related small fibre
neuropathy: a randomized controlled trial. Brain 142:263–275.
https://doi.org/10.1093/brain/awy329
28. Dib-Hajj S, Black JA, Cummins TR, Waxman SG (2002) NaN/
Nav1.9: a sodium channel with unique properties. Trends
Neurosci 25:253–259. https://doi.org/10.1016/s0166-2236(02)
02150-1
29. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S,
Tyrrell L, Marshall L, Waxman SG (2005) Gain-of-function mu-
tation in Nav1.7 in familial erythromelalgia induces bursting of
sensory neurons. Brain 128:1847–1854. https://doi.org/10.1093/
brain/awh514
30. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG (2007) From
genes to pain: Na v 1.7 and human pain disorders. Trends
Neurosci 30:555–563. https://doi.org/10.1016/j.tins.2007.08.004
31. Dib-Hajj SD, Black JA, Waxman SG (2015) NaV1.9: a sodium
channel linked to human pain. Nat Rev Neurosci 16:511–519.
https://doi.org/10.1038/nrn3977
32. Ding J, Zhang JW, Guo YX, Zhang YX, Chen ZH, Zhai QX
(2019) Novel mutations in SCN9A occurring with fever-
associated seizures or epilepsy. Seizure 71:214–218. https://doi.
org/10.1016/j.seizure.2019.06.005
33. Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen
JB (2005) SCN9A mutations define primary erythermalgia as a
neuropathic disorder of voltage gated sodium channels. J Invest
Dermatol 124:1333–1338. https://doi.org/10.1111/j.0022-202X.
2005.23737.x
34. Drissi I, Woods WA, Woods CG (2020) Understanding the ge-
netic basis of congenital insensitivity to pain. BrMed Bull. https://
doi.org/10.1093/bmb/ldaa003
35. Eberhardt M, Nakajima J, Klinger AB, Neacsu C, Huhne K,
O’Reilly AO, Kist AM, Lampe AK, Fischer K, Gibson J, Nau
C,Winterpacht A, Lampert A (2014) Inherited pain: sodium chan-
nel Nav1.7 A1632Tmutation causes erythromelalgia due to a shift
of fast inactivation. J Biol Chem 289:1971–1980. https://doi.org/
10.1074/jbc.M113.502211
36. Eijkenboom I, Sopacua M, Hoeijmakers JGJ, de Greef BTA,
Lindsey P, Almomani R, Marchi M, Vanoevelen J, Smeets
HJM, Waxman SG, Lauria G, Merkies ISJ, Faber CG, Gerrits
MM (2019) Yield of peripheral sodium channels gene screening
in pure small fibre neuropathy. J Neurol Neurosurg Psychiatry 90:
342–352. https://doi.org/10.1136/jnnp-2018-319042
37. Emery EC, Habib AM, Cox JJ, Nicholas AK, Gribble FM,Woods
CG, Reimann F (2015) Novel SCN9A mutations underlying ex-
treme pain phenotypes: unexpected electrophysiological and clin-
ical phenotype correlations. J Neurosci 35:7674–7681. https://doi.
org/10.1523/JNEUROSCI.3935-14.2015
38. Emery EC, Luiz AP, Wood JN (2016) Nav1.7 and other voltage-
gated sodium channels as drug targets for pain relief. Expert Opin
Ther Targets 20:975–983. https://doi.org/10.1517/14728222.
2016.1162295
39. Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman
EM, Macala LJ, Drenth JP, Waxman SG (2008) NaV1.7 gain-of-
function mutations as a continuum: A1632E displays physiologi-
cal changes associated with erythromelalgia and paroxysmal ex-
treme pain disorder mutations and produces symptoms of both
disorders. J Neurosci 28:11079–11088. https://doi.org/10.1523/
JNEUROSCI.3443-08.2008
40. Estacion M, Choi JS, Eastman EM, Lin Z, Li Y, Tyrrell L, Yang
Y, Dib-Hajj SD, Waxman SG (2010) Can robots patch-clamp as
well as humans? Characterization of a novel sodium channel mu-
tation. J Physiol 588:1915–1927. https://doi.org/10.1113/jphysiol.
2009.186114
41. Estacion M, Han C, Choi JS, Hoeijmakers JG, Lauria G, Drenth
JP, Gerrits MM, Dib-Hajj SD, Faber CG, Merkies IS, Waxman
SG (2011) Intra- and interfamily phenotypic diversity in pain syn-
dromes associated with a gain-of-function variant of NaV1.7. Mol
Pain 7:92. https://doi.org/10.1186/1744-8069-7-92
42. Estacion M, Yang Y, Dib-Hajj SD, Tyrrell L, Lin Z, Yang Y,
Waxman SG (2013) A new Nav1.7 mutat ion in an
erythromelalgia patient. Biochem Biophys Res Commun 432:
99–104. https://doi.org/10.1016/j.bbrc.2013.01.079
43. Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS,
Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S,
Drenth JP, Waxman SG, Merkies IS (2012) Gain of function
Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann
Neurol 71:26–39. https://doi.org/10.1002/ana.22485
44. Faber CG, Lauria G, Merkies IS, Cheng X, Han C, Ahn HS,
Persson AK, Hoeijmakers JG, Gerrits MM, Pierro T, Lombardi
R, Kapetis D, Dib-Hajj SD, Waxman SG (2012) Gain-of-function
Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S
A 109:19444–19449. https://doi.org/10.1073/pnas.1216080109
45. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV,
Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner
RM, Rees M (2006) SCN9A mutations in paroxysmal extreme
pain disorder: allelic variants underlie distinct channel defects
and phenotypes. Neuron 52:767–774. https://doi.org/10.1016/j.
neuron.2006.10.006
46. Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S,
Melanson M, Dib-Hajj SD, Waxman SG (2009) A novel
Nav1.7 mutation producing carbamazepine-responsive
876 Pflugers Arch - Eur J Physiol (2020) 472:865–880
erythromelalgia. Ann Neurol 65:733–741. https://doi.org/10.
1002/ana.21678
47. Fjell J, Hjelmstrom P, Hormuzdiar W, Milenkovic M, Aglieco F,
Tyrrell L, Dib-Hajj S, Waxman SG, Black JA (2000) Localization
of the tetrodotoxin-resistant sodium channel NaN in nociceptors.
Neuroreport 11:199–202. https://doi.org/10.1097/00001756-
200001170-00039
48. Ginanneschi F, Rubegni A, Moro F, Volpi N, Santorelli FM,
Rossi A (2019) SCN11A variant as possible pain generator in
sensory axonal neuropathy. Neurol Sci 40:1295–1297. https://
doi.org/10.1007/s10072-019-3703-4
49. Gingras J, Smith S, Matson DJ, Johnson D, Nye K, Couture L,
Feric E, Yin R, Moyer BD, Peterson ML, Rottman JB, Beiler RJ,
Malmberg AB, McDonough SI (2014) Global Nav1.7 knockout
mice recapitulate the phenotype of human congenital indifference
to pain. PLoS One 9:e105895. https://doi.org/10.1371/journal.
pone.0105895
50. Goldberg DS, McGee SJ (2011) Pain as a global public health
priority. BMC Public Health 11:770. https://doi.org/10.1186/
1471-2458-11-770
51. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube
MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B,
Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB,
Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley
BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN,
SamuelsME, Sherrington R, HaydenMR (2007) Loss-of-function
mutations in the Nav1.7 gene underlie congenital indifference to
pain in multiple human populations. Clin Genet 71:311–319.
https://doi.org/10.1111/j.1399-0004.2007.00790.x
52. Gwathmey KG, Pearson KT (2019) Diagnosis and management
of sensory polyneuropathy. BMJ 365:l1108. https://doi.org/10.
1136/bmj.l1108
53. Haberberger RV, Barry C, Dominguez N, Matusica D (2019)
Human dorsal root ganglia. Front Cell Neurosci 13:271. https://
doi.org/10.3389/fncel.2019.00271
54. Haehner A, Hummel T, Heinritz W, Krueger S, Meinhardt M,
Whitcroft KL, Sabatowski R, Gossrau G (2018) Mutation in
Nav 1.7 causes high olfactory sensitivity. Eur J Pain 22:1767–
1773. https://doi.org/10.1002/ejp.1272
55. Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L, Cao X,
Yang Y, Waxman SG (2009) Early- and late-onset inherited
erythromelalgia: genotype-phenotype correlation. Brain 132:
1711–1722. https://doi.org/10.1093/brain/awp078
56. Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH,
Lauria G, Dib-Hajj SD, Drenth JP, Faber CG, Merkies IS,
Waxman SG (2012) Functional profiles of SCN9A variants in
dorsal root ganglion neurons and superior cervical ganglion neu-
rons correlate with autonomic symptoms in small fibre neuropa-
thy. Brain 135:2613–2628. https://doi.org/10.1093/brain/aws187
57. Han C, Yang Y, de Greef BT, Hoeijmakers JG, Gerrits MM,
Verhamme C, Qu J, Lauria G, Merkies IS, Faber CG, Dib-Hajj
SD, Waxman SG (2015) The domain II S4-S5 linker in Nav1.9: a
missense mutation enhances activation, impairs fast inactivation,
and produces human painful neuropathy. NeuroMolecular Med
17:158–169. https://doi.org/10.1007/s12017-015-8347-9
58. Han C, Yang Y, Te Morsche RH, Drenth JP, Politei JM,Waxman
SG, Dib-Hajj SD (2017) Familial gain-of-function Nav1.9 muta-
tion in a painful channelopathy. J Neurol Neurosurg Psychiatry
88:233–240. https://doi.org/10.1136/jnnp-2016-313804
59. Harty TP, Dib-Hajj SD, Tyrrell L, Blackman R, Hisama FM, Rose
JB, Waxman SG (2006) Na(V)1.7 mutant A863P in
erythromelalgia: effects of altered activation and steady-state in-
activation on excitability of nociceptive dorsal root ganglion neu-
rons. J Neurosci 26:12566–12575. https://doi.org/10.1523/
JNEUROSCI.3424-06.2006
60. Hockley JR, Boundouki G, Cibert-Goton V, McGuire C, Yip PK,
Chan C, Tranter M, Wood JN, Nassar MA, Blackshaw LA, Aziz
Q, Michael GJ, Baker MD,Winchester WJ, Knowles CH, Bulmer
DC (2014) Multiple roles for NaV1.9 in the activation of visceral
afferents by noxious inflammatory, mechanical, and human
disease-derived stimuli. Pain 155:1962–1975. https://doi.org/10.
1016/j.pain.2014.06.015
61. Hockley JR, Tranter MM, McGuire C, Boundouki G, Cibert-
Goton V, Thaha MA, Blackshaw LA, Michael GJ, Baker MD,
Knowles CH, Winchester WJ, Bulmer DC (2016) P2Y receptors
sensitize mouse and human colonic nociceptors. J Neurosci 36:
2364–2376. https://doi.org/10.1523/JNEUROSCI.3369-15.2016
62. Hoeijmakers JG, Han C, Merkies IS, Macala LJ, Lauria G, Gerrits
MM, Dib-Hajj SD, Faber CG, Waxman SG (2012) Small nerve
fibres, small hands and small feet: a new syndrome of pain,
dysautonomia and acromesomelia in a kindred with a novel
NaV1.7 mutation. Brain 135:345–358. https://doi.org/10.1093/
brain/awr349
63. Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG,
Gerrits MM, Tyrrell L, Lauria G, Faber CG, Dib-Hajj SD,
Merkies IS, Waxman SG, Group PS (2014) Gain-of-function mu-
tations in sodium channel Na(v)1.9 in painful neuropathy. Brain
137:1627–1642. https://doi.org/10.1093/brain/awu079
64. Huang J, Vanoye CG, Cutts A, Goldberg YP, Dib-Hajj SD, Cohen
CJ, Waxman SG, George AL Jr (2017) Sodium channel NaV1.9
mutations associated with insensitivity to pain dampen neuronal
excitability. J Clin Invest 127:2805–2814. https://doi.org/10.1172/
JCI92373
65. Huang J, Estacion M, Zhao P, Dib-Hajj FB, Schulman B, Abicht
A, Kurth I, Brockmann K, Waxman SG, Dib-Hajj SD (2019) A
novel gain-of-function Nav1.9 mutation in a child with episodic
pain. Front Neurosci 13:918. https://doi.org/10.3389/fnins.2019.
00918
66. Imai N, Miyake N, Saito Y, Kobayashi E, Ikawa M, Manaka S,
Shiina M, Ogata K, Matsumoto N (2015) Short-lasting unilateral
neuralgiform headache attacks with ispilateral facial flushing is a
new variant of paroxysmal extreme pain disorder. J Headache Pain
16:519. https://doi.org/10.1186/s10194-015-0519-3
67. Ito M, Yamaguchi S, Omine T, Miyagi T, Arakaki O, Yamamoto
YI, Takahashi K (2019) Behavioral therapy ceased cold water
immersion dependence in a patient with familial erythromelalgia
caused by SCN9A mutation. JAAD Case Rep 5:806–808. https://
doi.org/10.1016/j.jdcr.2019.07.007
68. Jeong SY, Goto J, Hashida H, Suzuki T, Ogata K, Masuda N,
Hirai M, Isahara K, Uchiyama Y, Kanazawa I (2000)
Identification of a novel human voltage-gated sodium channel
alpha subunit gene, SCN12A. Biochem Biophys Res Commun
267:262–270. https://doi.org/10.1006/bbrc.1999.1916
69. Kabata R, Okuda H, Noguchi A, Kondo D, Fujiwara M, Hata K,
Kato Y, Ishikawa K, Tanaka M, Sekine Y, Hishikawa N,
Mizukami T, Ito J, Akasaka M, Sakurai K, Yoshida T, Minoura
H, Hayashi T, Inoshita K, Matsuyama M, Kinjo N, Cao Y, Inoue
S, Kobayashi H, HaradaKH,Youssefian S, Takahashi T, Koizumi
A (2018) Familial episodic limb pain in kindreds with novel
Nav1.9 mutations. PLoS One 13:e0208516. https://doi.org/10.
1371/journal.pone.0208516
70. King MK, Leipold E, Goehringer JM, Kurth I, Challman TD
(2017) Pain insensitivity: distal S6-segment mutations in
NaV1.9 emerge as critical hotspot. Neurogenetics 18:179–181.
https://doi.org/10.1007/s10048-017-0513-9
71. Kingwell K (2019) Nav1.7 withholds its pain potential. Nat Rev
Drug Discov. https://doi.org/10.1038/d41573-019-00065-0
72. Klein CJ, Wu Y, Kilfoyle DH, Sandroni P, Davis MD, Gavrilova
RH, Low PA, Dyck PJ (2013) Infrequent SCN9A mutations in
congenital insensitivity to pain and erythromelalgia. J Neurol
877Pflugers Arch - Eur J Physiol (2020) 472:865–880
Neurosurg Psychiatry 84:386–391. https://doi.org/10.1136/jnnp-
2012-303719
73. Kurban M, Wajid M, Shimomura Y, Christiano AM (2010) A
nonsense mutation in the SCN9A gene in congenital insensitivity
to pain. Dermatology 221:179–183. https://doi.org/10.1159/
000314692
74. Labau JIR, Estacion M, Tanaka BS, de Greef BTA, Hoeijmakers
JGJ, GeertsM, Gerrits MM, Smeets HJM, Faber CG,Merkies ISJ,
Lauria G, Dib-Hajj SD, Waxman SG (2020) Differential effect of
lacosamide on Nav1.7 variants from responsive and non-
responsive patients with small fibre neuropathy. Brain 143:771–
782. https://doi.org/10.1093/brain/awaa016
75. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC,
Porreca F (2002) Inhibition of neuropathic pain by decreased ex-
pression of the tetrodotoxin-resistant sodium channel, NaV1.8.
Pain 95:143–152. https://doi.org/10.1016/s0304-3959(01)00391-
8
76. Lampert A, Dib-Hajj SD, Eastman EM, Tyrrell L, Lin Z, Yang Y,
Waxman SG (2009) Erythromelalgia mutation L823R shifts acti-
vation and inactivation of threshold sodium channel Nav1.7 to
hyperpolarized potentials. Biochem Biophys Res Commun 390:
319–324. https://doi.org/10.1016/j.bbrc.2009.09.121
77. Lawson SN (2002) Phenotype and function of somatic primary
afferent nociceptive neurones with C-, adelta- or aalpha/beta-fi-
bres. Exp Physiol 87:239–244. https://doi.org/10.1113/
eph8702350
78. Lee MJ, Yu HS, Hsieh ST, Stephenson DA, Lu CJ, Yang CC
(2007) Characterization of a familial case with primary
erythromelalgia from Taiwan. J Neurol 254:210–214. https://doi.
org/10.1007/s00415-006-0328-3
79. Leipold E, Liebmann L, Korenke GC, Heinrich T, Giesselmann S,
Baets J, Ebbinghaus M, Goral RO, Stodberg T, Hennings JC,
Bergmann M, Altmuller J, Thiele H, Wetzel A, Nurnberg P,
Timmerman V, De Jonghe P, Blum R, Schaible HG, Weis J,
Heinemann SH, Hubner CA, Kurth I (2013) A de novo gain-of-
function mutation in SCN11A causes loss of pain perception. Nat
Genet 45:1399–1404. https://doi.org/10.1038/ng.2767
80. Leipold E, Hanson-Kahn A, Frick M, Gong P, Bernstein JA,
Voigt M, Katona I, Oliver Goral R, Altmuller J, Nurnberg P,
Weis J, Hubner CA, Heinemann SH, Kurth I (2015) Cold-
aggravated pain in humans caused by a hyperactive NaV1.9 chan-
nel mutant. Nat Commun 6:10049. https://doi.org/10.1038/
ncomms10049
81. Liu Z, Ye X, Qiao P, Luo W, Wu Y, He Y, Gao P (2019) G327E
mutation in SCN9A gene causes idiopathic focal epilepsy with
Rolandic spikes: a case report of twin sisters. Neurol Sci 40:
1457–1460. https://doi.org/10.1007/s10072-019-03752-3
82. Mann N, King T, Murphy R (2019) Review of primary and sec-
ondary erythromelalgia. Clin Exp Dermatol 44:477–482. https://
doi.org/10.1111/ced.13891
83. Marchi M, Provitera V, Nolano M, Romano M, Maccora S,
D’Amato I, Salvi E, Gerrits M, Santoro L, Lauria G (2018) A
novel SCN9A splicing mutation in a compound heterozygous girl
with congenital insensitivity to pain, hyposmia and hypogeusia. J
Peripher Nerv Syst 23:202–206. https://doi.org/10.1111/jns.
12280
84. Maruyama H, Yamamoto M, Matsutomi T, Zheng T, Nakata Y,
Wood JN, Ogata N (2004) Electrophysiological characterization
of the tetrodotoxin-resistant Na+ channel, Na(v)1.9, in mouse dor-
sal root ganglion neurons. Pflugers Arch 449:76–87. https://doi.
org/10.1007/s00424-004-1315-0
85. Meglic A, Perkovic-BenedikM, Trebusak PodkrajsekK, Bertok S
(2014) Painful micturition in a small child: an unusual clinical
picture of paroxysmal extreme pain disorder. Pediatr Nephrol
29:1643–1646. https://doi.org/10.1007/s00467-014-2819-2
86. Michiels JJ, te Morsche RH, Jansen JB, Drenth JP (2005)
Autosomal dominant erythermalgia associated with a novel mu-
tation in the voltage-gated sodium channel alpha subunit Nav1.7.
Arch Neurol 62:1587–1590. https://doi.org/10.1001/archneur.62.
10.1587
87. Minett MS, Pereira V, Sikandar S, Matsuyama A, Lolignier S,
Kanellopoulos AH, Mancini F, Iannetti GD, Bogdanov YD,
Santana-Varela S, Millet Q, Baskozos G, MacAllister R, Cox JJ,
Zhao J, Wood JN (2015) Endogenous opioids contribute to insen-
sitivity to pain in humans and mice lacking sodium channel
Nav1.7. Nat Commun 6:8967. https://doi.org/10.1038/
ncomms9967
88. Mohammed ZA, Doran C, Grundy D, Nassar MA (2017)
Veratridine produces distinct calcium response profiles in mouse
dorsal root ganglia neurons. Sci Rep 7:45221. https://doi.org/10.
1038/srep45221
89. Mohammed ZA, Kaloyanova K, Nassar MA (2020) An unbiased
and efficient assessment of excitability of sensory neurons for
analgesic drug discovery. Pain. 161:1100–1108. https://doi.org/
10.1097/j.pain.0000000000001802
90. Moore C, Gupta R, Jordt SE, Chen Y, Liedtke WB (2018)
Regulation of pain and itch by TRP channels. Neurosci Bull 34:
120–142. https://doi.org/10.1007/s12264-017-0200-8
91. Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA,
Dickenson AH, Wood JN (2004) Nociceptor-specific gene dele-
tion reveals a major role for Nav1.7 (PN1) in acute and inflamma-
tory pain. Proc Natl Acad Sci U S A 101:12706–12711. https://
doi.org/10.1073/pnas.0404915101
92. Nassar MA, Baker MD, Levato A, Ingram R, Mallucci G,
McMahon SB, Wood JN (2006) Nerve injury induces robust
allodynia and ectopic discharges in Nav1.3 null mutant mice.
Mol Pain 2:33. https://doi.org/10.1186/1744-8069-2-33
93. Okuda H, Noguchi A, Kobayashi H, Kondo D, Harada KH,
Youssefian S, Shioi H, Kabata R, Domon Y, Kubota K, Kitano
Y, Takayama Y, Hitomi T, Ohno K, Saito Y, Asano T, Tominaga
M, Takahashi T, Koizumi A (2016) Infantile pain episodes asso-
ciated with novel Nav1.9 mutations in familial episodic pain syn-
drome in Japanese families. PLoS One 11:e0154827. https://doi.
org/10.1371/journal.pone.0154827
94. Ostman JA, Nassar MA, Wood JN, Baker MD (2008) GTP up-
regulated persistent Na+ current and enhanced nociceptor excit-
ability require NaV1.9. J Physiol 586:1077–1087. https://doi.org/
10.1113/jphysiol.2007.147942
95. Padilla F, Couble ML, Coste B, Maingret F, Clerc N, Crest M,
Ritter AM, Magloire H, Delmas P (2007) Expression and locali-
zation of the Nav1.9 sodium channel in enteric neurons and in
trigeminal sensory endings: implication for intestinal reflex func-
tion and orofacial pain. Mol Cell Neurosci 35:138–152. https://
doi.org/10.1016/j.mcn.2007.02.008
96. Peddareddygari LR, Oberoi K, Grewal RP (2014) Congenital in-
sensitivity to pain: a case report and review of the literature. Case
Rep Neurol Med 2014:141953–141954. https://doi.org/10.1155/
2014/141953
97. Pereira V, Millet Q, Aramburu J, Lopez-Rodriguez C, Gaveriaux-
Ruff C, Wood JN (2018) Analgesia linked to Nav1.7 loss of func-
tion requires micro- and delta-opioid receptors. Wellcome Open
Res 3:101. https://doi.org/10.12688/wellcomeopenres.14687.1
98. Phatarakijnirund V, Mumm S, McAlister WH, Novack DV,
Wenkert D, Clements KL, Whyte MP (2016) Congenital insensi-
tivity to pain: fracturing without apparent skeletal pathobiology
caused by an autosomal dominant, second mutation in SCN11A
encoding voltage-gated sodium channel 1.9. Bone 84:289–298.
https://doi.org/10.1016/j.bone.2015.11.022
99. Priest BT,Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM,
Liberator P, Iyer LM, Kash SF, Kohler MG, Kaczorowski GJ,
MacIntyre DE, Martin WJ (2005) Contribution of the
878 Pflugers Arch - Eur J Physiol (2020) 472:865–880
tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to
sensory transmission and nociceptive behavior. Proc Natl Acad
Sci U S A 102:9382–9387. https://doi.org/10.1073/pnas.
0501549102
100. Rajasekharan S, Martens L, Domingues L, Cauwels R (2017)
SCN9A channelopathy associated autosomal recessive congenital
indifference to pain. A case report. Eur J Paediatr Dent 18:66–68.
https://doi.org/10.23804/ejpd.2017.18.01.14
101. Ritter AM, Martin WJ, Thorneloe KS (2009) The voltage-gated
sodium channel Nav1.9 is required for inflammation-based uri-
nary bladder dysfunction. Neurosci Lett 452:28–32. https://doi.
org/10.1016/j.neulet.2008.12.051
102. Rugiero F, Mistry M, Sage D, Black JA, Waxman SG, Crest M,
Clerc N, Delmas P, Gola M (2003) Selective expression of a
persistent tetrodotoxin-resistant Na+ current and NaV1.9 subunit
in myenteric sensory neurons. J Neurosci 23:2715–2725
103. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman
SG (2006) A single sodium channel mutation produces hyper- or
hypoexcitability in different types of neurons. Proc Natl Acad Sci
U S A 103:8245–8250. https://doi.org/10.1073/pnas.0602813103
104. Rush AM, Cummins TR, Waxman SG (2007) Multiple sodium
channels and their roles in electrogenesis within dorsal root gan-
glion neurons. J Physiol 579:1–14. https://doi.org/10.1113/
jphysiol.2006.121483
105. Sadler KE, Stucky CL (2019) Neuronal transient receptor poten-
tial (TRP) channels and noxious sensory detection in sickle cell
disease. Neurosci Lett 694:184–191. https://doi.org/10.1016/j.
neulet.2018.11.056
106. Sawal HA, Harripaul R, Mikhailov A, Dad R, Ayub M, Jawad
Hassan M, Vincent JB (2016) Biallelic truncating SCN9A muta-
tion identified in four families with congenital insensitivity to pain
from Pakistan. Clin Genet 90:563–565. https://doi.org/10.1111/
cge.12860
107. Shields SD, Deng L, Reese RM, Dourado M, Tao J, Foreman O,
Chang JH, Hackos DH (2018) Insensitivity to pain upon adult-
onset deletion of Nav1.7 or its blockade with selective inhibitors. J
Neurosci 38:10180–10201. https://doi.org/10.1523/JNEUROSCI.
1049-18.2018
108. Shorer Z, Wajsbrot E, Liran TH, Levy J, Parvari R (2014) A novel
mutation in SCN9A in a child with congenital insensitivity to pain.
Pediatr Neurol 50:73–76. https://doi.org/10.1016/j.pediatrneurol.
2013.09.007
109. Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe
P, Thompson J, DixonM, Gurnett C, Peiffer A,White HS, Filloux
F, Leppert MF (2009) A role of SCN9A in human epilepsies, as a
cause of febrile seizures and as a potential modifier of Dravet
syndrome. PLoS Genet 5:e1000649. https://doi.org/10.1371/
journal.pgen.1000649
110. Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I,
Richardson RC (2012) Severe case and literature review of prima-
ry erythromelalgia: novel SCN9A gene mutation. Vasc Med 17:
44–49. https://doi.org/10.1177/1358863X11422584
111. Snape A, Pittaway JF, Baker MD (2010) Excitability parameters
and sensitivity to anemone toxin ATX-II in rat small diameter
primary sensory neurones discriminated by Griffonia simplicifolia
isolectin IB4. J Physiol 588:125–137. https://doi.org/10.1113/
jphysiol.2009.181107
112. Sopacua M, Hoeijmakers JGJ, Merkies ISJ, Lauria G, Waxman
SG, Faber CG (2019) Small-fiber neuropathy: expanding the clin-
ical pain universe. J Peripher Nerv Syst 24:19–33. https://doi.org/
10.1111/jns.12298
113. Stirling LC, Forlani G, Baker MD, Wood JN, Matthews EA,
Dickenson AH, Nassar MA (2005) Nociceptor-specific gene de-
letion using heterozygous NaV1.8-Cre recombinase mice. Pain
113:27–36. https://doi.org/10.1016/j.pain.2004.08.015
114. Suter MR, Bhuiyan ZA, Laedermann CJ, Kuntzer T, Schaller M,
StauffacherMW, Roulet E, Abriel H, Decosterd I,Wider C (2015)
p.L1612P, a novel voltage-gated sodium channel Nav1.7mutation
inducing a cold sensitive paroxysmal extreme pain disorder.
Anesthesiology 122:414–423. https://doi.org/10.1097/ALN.
0000000000000476
115. Tanaka BS, Nguyen PT, Zhou EY, Yang Y, Yarov-Yarovoy V,
Dib-Hajj SD, Waxman SG (2017) Gain-of-function mutation of a
voltage-gated sodium channel NaV1.7 associated with peripheral
pain and impaired limb development. J Biol Chem 292:9262–
9272. https://doi.org/10.1074/jbc.M117.778779
116. Tham SW, Giles M (2018) Current pain management strategies
for patients with erythromelalgia: a critical review. J Pain Res 11:
1689–1698. https://doi.org/10.2147/JPR.S154462
117. Themistocleous AC, Ramirez JD, Serra J, Bennett DL (2014) The
clinical approach to small fibre neuropathy and painful channelop-
athy. Pract Neurol 14:368–379. https://doi.org/10.1136/
practneurol-2013-000758
118. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T,
Levinson SR, Wolf JJ, Silos-Santiago I, Halegoua S, Mandel G
(1997) Identification of PN1, a predominant voltage-dependent
sodium channel expressed principally in peripheral neurons.
Proc Natl Acad Sci U S A 94:1527–1532. https://doi.org/10.
1073/pnas.94.4.1527
119. Vetter I, Deuis JR, Mueller A, Israel MR, Starobova H, Zhang A,
Rash LD, Mobli M (2017) NaV1.7 as a pain target-from gene to
pharmacology. Pharmacol Ther 172:73–100. https://doi.org/10.
1016/j.pharmthera.2016.11.015
120. Wang Y,Mi J, Lu K, Lu Y,Wang K (2015) Comparison of gating
properties and use-dependent block of Nav1.5 and Nav1.7 chan-
nels by anti-arrhythmics mexiletine and lidocaine. PLoS One 10:
e0128653. https://doi.org/10.1371/journal.pone.0128653
121. Waxman SG, Kocsis JD, Black JA (1994) Type III sodium chan-
nel mRNA is expressed in embryonic but not adult spinal sensory
neurons, and is reexpressed following axotomy. J Neurophysiol
72:466–470. https://doi.org/10.1152/jn.1994.72.1.466
122. Waxman SG, Dib-Hajj S, Cummins TR, Black JA (1999) Sodium
channels and pain. Proc Natl Acad Sci U S A 96:7635–7639.
https://doi.org/10.1073/pnas.96.14.7635
123. Wu MT, Huang PY, Yen CT, Chen CC, Lee MJ (2013) A novel
SCN9A mutation responsible for primary erythromelalgia and is
resistant to the treatment of sodium channel blockers. PLoSOne 8:
e55212. https://doi.org/10.1371/journal.pone.0055212
124. Wu B, Zhang Y, Tang H, Yang M, Long H, Shi G, Tang J, Shi X
(2017) A novel SCN9A mutation (F826Y) in primary
erythromelalgia alters the excitability of Nav1.7. Curr Mol Med
1 7 : 4 5 0 – 4 5 7 . h t t p s : / / d o i . o r g / 1 0 . 2 1 7 4 /
1566524017666171009105029
125. YangY,WangY, Li S, Xu Z, Li H,Ma L, Fan J, Bu D, Liu B, Fan
Z, Wu G, Jin J, Ding B, Zhu X, Shen Y (2004) Mutations in
SCN9A, encoding a sodium channel alpha subunit, in patients
with primary erythermalgia. J Med Genet 41:171–174. https://
doi.org/10.1136/jmg.2003.012153
126. Yang Y, Huang J, Mis MA, Estacion M, Macala L, Shah P,
Schulman BR, Horton DB, Dib-Hajj SD, Waxman SG (2016)
Nav1.7-A1632G mutation from a family with inherited
erythromelalgia: enhanced firing of dorsal root ganglia neurons
evoked by thermal stimuli. J Neurosci 36:7511–7522. https://
doi.org/10.1523/JNEUROSCI.0462-16.2016
127. Yang C, Hua Y, Zhang W, Xu J, Xu L, Gao F, Jiang P (2018)
Variable epilepsy phenotypes associated with heterozygous muta-
tion in the SCN9A gene: report of two cases. Neurol Sci 39:1113–
1115. https://doi.org/10.1007/s10072-018-3300-y
128. Yekkirala AS, Roberson DP, Bean BP,Woolf CJ (2017) Breaking
barriers to novel analgesic drug development. Nat Rev Drug
Discov 16:545–564. https://doi.org/10.1038/nrd.2017.87
879Pflugers Arch - Eur J Physiol (2020) 472:865–880
129. Yu YQ, Zhao F, Guan SM, Chen J (2011) Antisense-mediated
knockdown of Na(V)1.8, but not Na(V)1.9, generates inhibitory
effects on complete Freund’s adjuvant-induced inflammatory pain
in rat. PLoS One 6:e19865. https://doi.org/10.1371/journal.pone.
0019865
130. ZhangXY,Wen J, YangW,Wang C, Gao L, Zheng LH,Wang T,
Ran K, Li Y, Li X, Xu M, Luo J, Feng S, Ma X, Ma H, Chai Z,
Zhou Z, Yao J, Zhang X, Liu JY (2013) Gain-of-function muta-
tions in SCN11A cause familial episodic pain. Am J Hum Genet
93:957–966. https://doi.org/10.1016/j.ajhg.2013.09.016
131. Zhang Z, Schmelz M, Segerdahl M, Quiding H, Centerholt C,
Jureus A, Carr TH, Whiteley J, Salter H, Kvernebo MS,
Orstavik K, Helas T, Kleggetveit IP, Lunden LK, Jorum E
(2014) Exonic mutations in SCN9A (NaV1.7) are found in a mi-
nority of patients with erythromelalgia. Scand J Pain 5:217–225.
https://doi.org/10.1016/j.sjpain.2014.09.002
132. Zhang T, Chen M, Zhu A, Zhang X, Fang T (2020) Novel muta-
tion of SCN9A gene causing generalized epilepsy with febrile
seizures plus in a Chinese family. Neurol Sci. https://doi.org/10.
1007/s10072-020-04284-x
133. Zhao F, Li X, Jin L, Zhang F, Inoue M, Yu B, Cao Z (2016)
Development of a rapid throughput assay for identification of
hNav1.7 antagonist using unique efficacious sodium channel ag-
onist, antillatoxin. Mar Drugs 14. https://doi.org/10.3390/
md14020036
134. Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW,
Kobayashi J, Nau C, Wood JN, Reeh PW (2007) Sensory neuron
sodium channel Nav1.8 is essential for pain at low temperatures.
Nature 447:855–858. https://doi.org/10.1038/nature05880
135. Zufall F, Pyrski M, Weiss J, Leinders-Zufall T (2012) Link be-
tween pain and olfaction in an inherited sodium channelopathy.
Arch Neurol 69:1119–1123. https://doi.org/10.1001/archneurol.
2012.21
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
880 Pflugers Arch - Eur J Physiol (2020) 472:865–880
